FY2025 EPS Estimates for CervoMed Lowered by Chardan Capital

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Analysts at Chardan Capital cut their FY2025 earnings per share estimates for shares of CervoMed in a research note issued on Monday, March 24th. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings of ($2.68) per share for the year, down from their prior estimate of ($1.22). Chardan Capital currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share.

CRVO has been the subject of a number of other reports. Roth Mkm increased their price target on CervoMed from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, March 18th. D. Boral Capital reissued a "buy" rating and set a $10.00 price target on shares of CervoMed in a research note on Wednesday, March 26th. Morgan Stanley reaffirmed an "underweight" rating on shares of CervoMed in a research note on Wednesday, December 11th. Brookline Capital Management upgraded shares of CervoMed from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Finally, HC Wainwright lowered shares of CervoMed from a "buy" rating to a "neutral" rating in a report on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $27.50.

Remove Ads

CervoMed Trading Down 2.4 %

NASDAQ:CRVO traded down $0.22 on Thursday, hitting $9.26. The company had a trading volume of 359,678 shares, compared to its average volume of 4,698,518. The firm has a 50 day moving average of $4.00 and a two-hundred day moving average of $7.53. The stock has a market capitalization of $80.55 million, a price-to-earnings ratio of -4.57 and a beta of 1.84. CervoMed has a 52 week low of $1.80 and a 52 week high of $25.92.

CervoMed (NASDAQ:CRVO - Get Free Report) last posted its earnings results on Monday, March 17th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.13). The company had revenue of $2.16 million during the quarter, compared to the consensus estimate of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in CRVO. Barclays PLC increased its holdings in CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company's stock worth $113,000 after purchasing an additional 5,919 shares in the last quarter. Perigon Wealth Management LLC acquired a new position in shares of CervoMed during the 4th quarter valued at $147,000. State Street Corp boosted its position in shares of CervoMed by 28.1% during the 3rd quarter. State Street Corp now owns 104,456 shares of the company's stock worth $1,525,000 after purchasing an additional 22,903 shares in the last quarter. Geode Capital Management LLC increased its position in CervoMed by 13.9% in the 3rd quarter. Geode Capital Management LLC now owns 114,934 shares of the company's stock valued at $1,678,000 after buying an additional 14,042 shares in the last quarter. Finally, Cornerstone Wealth Management LLC acquired a new position in CervoMed during the 4th quarter worth approximately $48,000. 25.15% of the stock is owned by institutional investors and hedge funds.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.